Join to View Full Profile
622 West 168th StreetNew York, NY 10032
Phone+1 212-305-4308
Dr. Mor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2009 - 2011- NYU Grossman School of MedicineFellowship, Rheumatology, 2003 - 2005
Tel Aviv University SacklerClass of 1999
Certifications & Licensure
NY State Medical License 2011 - 2026
NJ State Medical License 2013 - 2017
Publications & Presentations
PubMed
- Understanding the Therapeutic Potential of PD-1 Agonism in Inflammatory and Autoimmune Disorders.Justin Zhong, Ruijiang Song, Nacim Kerrouche, Xinyu Yu, Yotam Levin
Biodrugs. 2026-05-13 - Understanding the Inflammatory Aspect of Osteoarthritis: Lessons from Immune Checkpoint Inhibitors.Daniel M Portnoy, Matthieu Paiola, Carly Tymm, Robert Winchester, Adam Mor
Journal of Clinical Medicine. 2026-01-14 - Tubulointerstitial inflammation driving interstitial fibrosis and tubular atrophy predicts poor renal outcome in refractory lupus nephritis.Yevgeniya Gartshteyn, Shuwei Wang, Laura Geraldino-Pardilla, Adam Mor, Vivette D D'Agati
Rheumatology. 2026-01-08
Journal Articles
- Review Targeting the Programmed Cell Death-1 Pathway in Rheumatoid ArthritisAdam Mor, Greg J. Silverman, Sabina Sandigursky, ScienceDirect
Press Mentions
“Double Life” of Key Immune Protein Reveals New Strategies for Treating Cancer and Autoimmune DiseasesMarch 10th, 2024- “Double Life” of Key Immune Protein Reveals New Strategies for Treating Cancer and Autoimmune DiseasesMarch 15th, 2024
Grant Support
- The role of tissue-resident T cells in osteoarthritis during the transition to inflammatory arthritis induced by immune checkpoint inhibitorsCOLUMBIA UNIVERSITY HEALTH SCIENCES2026–2028
- A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2027
- A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2027
- Novel mechanisms regulating PD-1 signaling and functionCOLUMBIA UNIVERSITY HEALTH SCIENCES2016–2027
- PAG is a novel target in immunotherapyCOLUMBIA UNIVERSITY HEALTH SCIENCES2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
